Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
A Multicenter, Open Label, Randomized Phase II Trial of the MEK Inhibitor Pimasertib or Dacarbazine in Previously Untreated Subjects With N-Ras Mutated Locally Advanced or Metastatic Malignant Cutaneous Melanoma
Sponsor: EMD Serono
This PHASE2 trial investigates N-Ras Mutated Locally Advanced or Metastasis Malignant Cutaneous Melanoma and is currently completed. EMD Serono leads this study, which shows 9 recorded versions since 2012 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
9 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Jan 2019 — Jan 2021 [monthly]
Completed PHASE2
▶ Show 4 earlier versions
-
Jun 2018 — Jan 2019 [monthly]
Completed PHASE2
-
Jan 2018 — Jun 2018 [monthly]
Completed PHASE2
-
Feb 2017 — Jan 2018 [monthly]
Completed PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE2
First recorded
Dec 2012
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- EMD Serono
- Merck KGaA, Darmstadt, Germany
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, SA, Australia , Albury/Wodonga, Australia , Auchenflower, Australia , Augsburg, Germany , Badalona, Spain , Barcelona, Spain , Bari, Italy , Basel, Switzerland , Berlin, Germany , Birmingham, United States and 91 more locations